Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
Outset Medical, Inc. (OM) reported a proposed sale under Rule 144 of 383 shares of Common Stock through Morgan Stanley Smith Barney, with an aggregate market value of $4,933.04, targeted for sale on 08/15/2025 on NASDAQ. The filing shows the securities were acquired as settlement of vested restricted stock units on 08/15/2025 (748 shares) as equity compensation. The filer also reports a prior sale of 396 shares on 05/15/2025 that generated $7,057.86. The notice includes the customary representation that the seller is not aware of undisclosed material adverse information.
Form 144 filing for Outset Medical, Inc. (OM) documents a proposed sale of 243 shares of Common Stock through Morgan Stanley Smith Barney with an aggregate market value of $3,129.84, to be sold on 08/15/2025 on NASDAQ. The shares were acquired on 08/15/2025 as settlement of vested restricted stock units and were paid as equity compensation for services. The filer also disclosed a prior sale of 252 shares on 05/15/2025 generating gross proceeds of $4,490.50. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.